• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of Daratumumab on Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Are Planned to Receive Autologous Transplantation: What's the Relevance?

作者信息

Sgherza Nicola, Musto Pellegrino

机构信息

Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy.

Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.

出版信息

Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024073. doi: 10.4084/MJHID.2024.073. eCollection 2024.

DOI:10.4084/MJHID.2024.073
PMID:39258180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11385594/
Abstract
摘要

相似文献

1
Effects of Daratumumab on Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Are Planned to Receive Autologous Transplantation: What's the Relevance?达雷妥尤单抗对计划接受自体移植的多发性骨髓瘤患者造血干细胞的影响：有何关联？
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024073. doi: 10.4084/MJHID.2024.073. eCollection 2024.
2
[Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].[达雷妥尤单抗用于新诊断多发性骨髓瘤自体造血干细胞移植后的维持治疗]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1016-1021. doi: 10.3760/cma.j.issn.0253-2727.2023.12.008.
3
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.
4
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
5
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.自体造血干细胞移植继以异基因或自体造血干细胞移植治疗多发性骨髓瘤患者（BMT CTN 0102）：一项 3 期生物学任务试验。
Lancet Oncol. 2011 Dec;12(13):1195-203. doi: 10.1016/S1470-2045(11)70243-1. Epub 2011 Sep 29.
6
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.预防性左氧氟沙星对接受自体造血干细胞移植的多发性骨髓瘤中性粒细胞减少患者血流感染率和发热的影响。
Biol Blood Marrow Transplant. 2015 Oct;21(10):1808-14. doi: 10.1016/j.bbmt.2015.06.017. Epub 2015 Jul 3.
7
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
8
Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis.自体造血干细胞移植治疗多发性骨髓瘤患者的系统评价和荟萃分析。
Hematology. 2024 Dec;29(1):2343164. doi: 10.1080/16078454.2024.2343164. Epub 2024 Apr 23.
9
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.达雷妥尤单抗对多发性骨髓瘤患者自体干细胞移植中干细胞动员和采集、植入和移植后早期并发症的影响。
Leuk Lymphoma. 2023 Dec;64(13):2140-2147. doi: 10.1080/10428194.2023.2253479. Epub 2023 Sep 1.
10
[Retrospective clinical study on cryopreservation-free integrated autologous hematopoietic stem cell transplantation model for newly diagnosed multiple myeloma].[新诊断多发性骨髓瘤无冷冻保存的自体造血干细胞移植一体化模型的回顾性临床研究]
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):488-494. doi: 10.3760/cma.j.cn121090-20230929-00152.

本文引用的文献

1
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy.达雷妥尤单抗对适合自体移植的多发性骨髓瘤患者造血干细胞采集及植入的影响：比较硼替佐米、沙利度胺和地塞米松（VTd）与VTd联合达雷妥尤单抗（D-VTd）作为诱导治疗的真实世界PRIMULA研究结果
Ann Hematol. 2024 Oct;103(10):4345-4347. doi: 10.1007/s00277-024-05933-3. Epub 2024 Aug 22.
2
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.抗CD38单克隆抗体疗法对多发性骨髓瘤患者CD34+造血干细胞动员、采集及植入的影响——一项系统评价
Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944.
3
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis.在标准硼替佐米-沙利度胺-地塞米松方案中加入达雷妥尤单抗对造血干细胞动员与采集、移植后植入及感染并发症的影响：一项病例对照多中心真实世界分析
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024049. doi: 10.4084/MJHID.2024.049. eCollection 2024.
4
Impact of Daratumumab on Stem Cell Mobilization and Transplant in Patient with Newly Diagnosed Multiple Myeloma: A Real Word Single-Centre Study.达雷妥尤单抗对新诊断多发性骨髓瘤患者干细胞动员及移植的影响：一项真实世界单中心研究
Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024041. doi: 10.4084/MJHID.2024.041. eCollection 2024.
5
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.达雷妥尤单抗对新诊断多发性骨髓瘤患者干细胞产量的影响：来自多发性骨髓瘤研究组的报告
Bone Marrow Transplant. 2024 Jun;59(6):896-898. doi: 10.1038/s41409-024-02260-z. Epub 2024 Mar 9.
6
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.来那度胺或达雷妥尤单抗预先暴露对多发性骨髓瘤患者造血干细胞采集和重建的影响。
Ann Hematol. 2024 Oct;103(10):3839-3853. doi: 10.1007/s00277-024-05683-2. Epub 2024 Mar 6.
7
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.抗 CD38 单克隆抗体可损害多发性骨髓瘤患者 CD34+细胞的动员，并影响其集落形成能力。
Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667.
8
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
9
Insight into the mechanism of CD34 cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.深入了解接受抗CD38治疗的多发性骨髓瘤患者中CD34细胞动员受损的机制。
Br J Haematol. 2024 Apr;204(4):1439-1449. doi: 10.1111/bjh.19141. Epub 2023 Oct 9.
10
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.新诊断多发性骨髓瘤（MASTER）中基于微小残留病灶反应的适应性治疗：多中心、单臂、2 期试验的最终报告。
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.